|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Replogle, JMichael, Zhou, W, Amaro, AE, McFarland, JM, Villalobos-Ortiz, M, Ryan, J, Letai, A, Yilmaz, O, Sheltzer, J, Lippard, SJ, Ben-David, U, Amon, A|
|Journal||Proc Natl Acad Sci U S A|
|Date Published||2020 Dec 01|
Aneuploidy, defined as whole chromosome gains and losses, is associated with poor patient prognosis in many cancer types. However, the condition causes cellular stress and cell cycle delays, foremost in G1 and S phase. Here, we investigate how aneuploidy causes both slow proliferation and poor disease outcome. We test the hypothesis that aneuploidy brings about resistance to chemotherapies because of a general feature of the aneuploid condition-G1 delays. We show that single chromosome gains lead to increased resistance to the frontline chemotherapeutics cisplatin and paclitaxel. Furthermore, G1 cell cycle delays are sufficient to increase chemotherapeutic resistance in euploid cells. Mechanistically, G1 delays increase drug resistance to cisplatin and paclitaxel by reducing their ability to damage DNA and microtubules, respectively. Finally, we show that our findings are clinically relevant. Aneuploidy correlates with slowed proliferation and drug resistance in the Cancer Cell Line Encyclopedia (CCLE) dataset. We conclude that a general and seemingly detrimental effect of aneuploidy, slowed proliferation, provides a selective benefit to cancer cells during chemotherapy treatment.
|Alternate Journal||Proc Natl Acad Sci U S A|